Amlodipine Besylate Tablet
Product Images NDC 71610-732

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Amlodipine Besylate (NDC 71610-732). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 2.5 mg (71610 0732 15)

Amlodipine Besylate USP 2.5 mg oral tablets label showing a package of 15 tablets. The label includes storage instructions, manufacturer info (Teva Pharmaceutical Industries and packaging by Athena Pharma, Cookeville, TN), NDC number 71610-0732-15, batch number, and GTIN barcodes.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Chemical Structure (Image 1)

Chemical structure diagram of amlodipine besylate, showing its molecular framework with labeled atoms and bonds, including chlorine, nitrogen, oxygen, carbon, and hydrogen elements, alongside the molecular formula C20H25ClN2O5S displayed below the structure.*

FDA Label Image

\\client\x$\products\amlodipine Besylate Tabs (076846)\submissions\2017-11-29 Cbe-0 (AJK\Working\INSERT\Image Files\AmlodipineTab-fig01.jpg)

A line graph comparing event rates over time (in months) between placebo and Amlodipine groups. The y-axis represents event rate from 0 to 0.25, and the x-axis shows time points from 0 to 24 months with numbers at risk beneath. The graph includes statistical data: p-value 0.003, hazard ratio 0.691, and 95% confidence interval (0.54, 0.88).*

FDA Label Image

\\client\x$\products\amlodipine Besylate Tabs (076846)\submissions\2017-11-29 Cbe-0 (AJK\Working\INSERT\Image Files\AmlodipineTab-fig02.jpg)

A forest plot chart showing hazard ratios with 95% confidence intervals for different patient subgroups comparing Amlodipine Besylate treatment versus placebo. Subgroups include overall population, by age, gender, baseline sitting systolic blood pressure, baseline vessel disease, baseline vessels with stenosis, and PCI-stent strata, with the scale ranging from 0 to 2.0 favoring either Amlodipine or placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.